Skip to content

The diagnostic value of FGF21, adiponectin, and ß - klotho in schizophrenia and the impact of antipsychotic drugs on their levels

The diagnostic value of FGF21, adiponectin, and ß - klotho in schizophrenia and their changes after antipsychotic drug treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500097350
Enrollment
Unknown
Registered
2025-02-18
Start date
2025-02-18
Completion date
Unknown
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Case group:None
Control group:None

Sponsors

The Eighth People's Hospital of Zhengzhou City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Case group: (1) Relapsed patients aged 18~45 years old who have not taken medication for the first time or within 4 weeks, both men and women; (2) Mental score consistent with the International Classification and Diagnostic Criteria for Mental Disorders, 10th Edition (ICD-10).diagnostic criteria for schizome; (3) no history of electroconvulsive therapy; (4) Junior high school or above, good compliance, able to cooperate with the completion of cognitive function assessment; (5) Patients and their families have informed consent and signed the informed consent form. Control group: (1) no mental illness and no family history of mental illness; (2) Age 18~45 years old, male or female; (3) Junior high school or above, good compliance, able to cooperate with the completion of cognitive function assessment.

Exclusion criteria

Exclusion criteria: (1) Drug allergies; (2) the presence of severe organic diseases; (3) Those with metabolic diseases, immune, endocrine system related diseases or other systemic diseases; (4) Pregnant and lactating women; (5) Those who have been treated with antidepressant, anti-anxiety, antipsychotic drugs or mood stabilizers in the past 4 weeks; (6) BMI25; (7) Those who abuse psychoactive substances such as drugs or alcohol.

Design outcomes

Primary

MeasureTime frame
FGF21 serum levels;FGF21 serum levels;FGF21 serum levels;

Secondary

MeasureTime frame
Biochemical indicators;Clinical symptoms of schizophrenia;Cognitive Function;Adverse reactions;

Countries

China

Contacts

Public ContactMeng Li

The Eighth People's Hospital of Zhengzhou City

menglee726@qq.com+86 371 80953709

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026